FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598392444> ?p ?o ?g. }

• W2598392444 abstract "Abstract Abstract 3187 Thromboembolism (TE) is an important complication of cancer with substantial clinical implications. MM, treated with thalidomide (thal) and LEN, has TE rates up to 25%, particularly when used in combination with chemotherapy and corticosteroids. Given disease heterogeneity, bleeding and TE risks are different for all patients and individuals over time. With the emergence of novel antithrombotic agents, further understanding of the pathophysiology of both MM- and therapy-related hemostatic dysfunction and the identification of important biomarkers, may promote a risk-stratification process and allow a targeted therapeutic strategy. We prospectively and sequentially assessed novel thrombogenic biomarkers, with a plan to correlate with functional assays (thrombin generation and microparticles) in R-MM, before and after exposure to LEN/dex as part of a 150-patient phase-II clinical trial. Hemostatic assessments were performed at enrolment, 1-, 4-, 12-months and/or end of study. 27 patients at our institution, 15 males, median age 69 years (range 58–80) were included in the analysis: 16 had IgG monoclonal protein (13 kappa [k]), 9 IgA (6 k), 2 were k light chain only. The karyotype was diploid in 18, complex in 4 and 3 patients had t(4;14), t(11;14) or t(8;14) respectively. Median number of prior lines of therapy was 3 (range 1–7); 18 had prior thal and 15 had received a melphalan-based autologous stem cell transplant. Median (range) for Hb was 111g/L (80-137) and creatinine clearance 66.6mL/min (23-182). 6/27 had a prior TE: 1 arterial, 5 venous. All patients commenced antithrombotic therapy at enrolment: 20 received aspirin (100mg/day), 4 prophylactic and 2 therapeutic dose enoxaparin, 1 treatment dose warfarin. At enrolment (pre-LEN/dex) and after 4 weeks of therapy, the median (range) for the individual assays are outlined in table 1. Pre-LEN/dex: FVIIIc, vWFAg, Fib Mon, TAT, PF1+2 and TM were markedly elevated in the majority of patients. After 4 weeks of therapy, many biomarkers remained elevated, however, Fib Mon and PMN-E near normalised in all patients; FVIIIC and vWFAg was elevated in less patients; while Fib, PF1+2 and TAT increased. This early promising data demonstrate inflammatory, endothelial and hemostatic dysregulation in R-MM with an altered biomarker profile after exposure to LEN/dex. Further results of sequential analyses will be presented at the meeting. Study (cycle, day) C1D1 (pre–LEN/dex) n* C2D1 (4–weeks LEN/dex) n* Biomarker (units, NR) Median Range >ULN, <LLN Median Range >ULN <LLN APTT (s, 24–34) 34 24–48 13 0 33 26–52 8 0 PT (s, 11.8–14.6) 13.5 12–25.6 10 0 13.2 11.2–45.2 2 3 Fib (g/L, 2.0–4.0) 4 2.4–6.8 12 0 5.5 0.7–8.4 21 2 D-dimer (mg/L, 0.0–0.5) 0.5 0.1-1.5 9 NA 0.6 0.1–6.4 15 NA Plt (×109/L, 150–450) 214 43–372 0 7 225 30–385 0 6 FVIIIc (%, 50–150) 298 96–600 22 0 236.5 159–600 10 0 vWFAg (%, 50–160) 206 98–325 18 0 298 148–364 12 0 APC-R ratio (2–3.5) 2.3 1.7–3.4 0 3 3.2 1.7–3.6 1 1 AT (%, 80–120) 98 69–135 3 3 108 77–126 4 1 Fib Mon (μg/ml, 0.1– 6) 4.3 2.0–61.2 8 0 3.1 0–95 2 1 TAT (μg/L, <2.0–4.2) 1.1 0.4–37.6 9 14 8.1 2.7–54.7 19 0 PF1+2 (pmol/L, 69–229) 192.3 0.7–705.5 11 2 197.3 35.8–1266.5 8 5 anti-CG (U/ml, <15) 0.2 0-5.2 0 NA 0.1 0–0.6 0 NA TM (pg/mL, 2353–4541) 4739.1 2628–11656.3 15 0 4050.3 244–10613.2 8 2 PMN-E (ng/mL, 0–90) 44 22–276 6 NA 34.8 14–92 1 NA NR: Normal range; APTT: Activated partial thromboplastin time; PT: Prothrombin time; Fib: Fibrinogen; Plt: Platelet count; FVIIIc: Factor VIII-coagulant; vWFAg: von Willebrand factor Antigen; APC-R: Activated protein C resistance ratio; AT: Antithrombin; Fib Mon: Fibrin Monomers; TAT: Thrombin-antithrombin complex; PF1+2: Prothrombin fragments1+2; CG: Cathepsin G; TM: Thrombomodulin; PMN-E: PMN Elastase; NA: values <LLN or >ULN not clinically applicable. * Number of patients (n) within the cohort (n=27), in whom measured level was >upper limit of normal (>ULN) or <lower limit of normal (<LLN). Disclosures: Curnow: Celgene: Research Funding; Novartis: Consultancy. Lynch:Celgene Pty Ltd: Employment, Equity Ownership. Harrison:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Prince:Celegene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Westerman:Celgene: Research Funding." @default.
• W2598392444 created "2017-04-07" @default.
• W2598392444 creator A5009177955 @default.
• W2598392444 creator A5017234565 @default.
• W2598392444 creator A5021020612 @default.
• W2598392444 creator A5027487207 @default.
• W2598392444 creator A5042336840 @default.
• W2598392444 creator A5042980483 @default.
• W2598392444 creator A5053768191 @default.
• W2598392444 creator A5059373877 @default.
• W2598392444 creator A5071712855 @default.
• W2598392444 creator A5091396091 @default.
• W2598392444 date "2010-11-19" @default.
• W2598392444 modified "2023-09-28" @default.
• W2598392444 title "Novel Thrombogenic Biomarkers In Patients with Relapsed/Refractory Multiple Myeloma (MM) Treated with Lenalidomide (LEN) and Dexamethasone (Dex) Therapy" @default.
• W2598392444 doi "https://doi.org/10.1182/blood.v116.21.3187.3187" @default.
• W2598392444 hasPublicationYear "2010" @default.
• W2598392444 type Work @default.
• W2598392444 sameAs 2598392444 @default.
• W2598392444 citedByCount "0" @default.
• W2598392444 crossrefType "journal-article" @default.
• W2598392444 hasAuthorship W2598392444A5009177955 @default.
• W2598392444 hasAuthorship W2598392444A5017234565 @default.
• W2598392444 hasAuthorship W2598392444A5021020612 @default.
• W2598392444 hasAuthorship W2598392444A5027487207 @default.
• W2598392444 hasAuthorship W2598392444A5042336840 @default.
• W2598392444 hasAuthorship W2598392444A5042980483 @default.
• W2598392444 hasAuthorship W2598392444A5053768191 @default.
• W2598392444 hasAuthorship W2598392444A5059373877 @default.
• W2598392444 hasAuthorship W2598392444A5071712855 @default.
• W2598392444 hasAuthorship W2598392444A5091396091 @default.
• W2598392444 hasConcept C126322002 @default.
• W2598392444 hasConcept C141071460 @default.
• W2598392444 hasConcept C143998085 @default.
• W2598392444 hasConcept C2776063141 @default.
• W2598392444 hasConcept C2776364478 @default.
• W2598392444 hasConcept C2778684742 @default.
• W2598392444 hasConcept C71924100 @default.
• W2598392444 hasConcept C90924648 @default.
• W2598392444 hasConceptScore W2598392444C126322002 @default.
• W2598392444 hasConceptScore W2598392444C141071460 @default.
• W2598392444 hasConceptScore W2598392444C143998085 @default.
• W2598392444 hasConceptScore W2598392444C2776063141 @default.
• W2598392444 hasConceptScore W2598392444C2776364478 @default.
• W2598392444 hasConceptScore W2598392444C2778684742 @default.
• W2598392444 hasConceptScore W2598392444C71924100 @default.
• W2598392444 hasConceptScore W2598392444C90924648 @default.
• W2598392444 hasLocation W25983924441 @default.
• W2598392444 hasOpenAccess W2598392444 @default.
• W2598392444 hasPrimaryLocation W25983924441 @default.
• W2598392444 hasRelatedWork W2525909300 @default.
• W2598392444 hasRelatedWork W2549632064 @default.
• W2598392444 hasRelatedWork W2555344161 @default.
• W2598392444 hasRelatedWork W2557799893 @default.
• W2598392444 hasRelatedWork W2562289938 @default.
• W2598392444 hasRelatedWork W2565353381 @default.
• W2598392444 hasRelatedWork W2571078417 @default.
• W2598392444 hasRelatedWork W2581557638 @default.
• W2598392444 hasRelatedWork W2583977108 @default.
• W2598392444 hasRelatedWork W2587378035 @default.
• W2598392444 hasRelatedWork W2596731463 @default.
• W2598392444 hasRelatedWork W2784498032 @default.
• W2598392444 hasRelatedWork W2909968155 @default.
• W2598392444 hasRelatedWork W2912545964 @default.
• W2598392444 hasRelatedWork W2914485485 @default.
• W2598392444 hasRelatedWork W2915861299 @default.
• W2598392444 hasRelatedWork W2979736044 @default.
• W2598392444 hasRelatedWork W2979843782 @default.
• W2598392444 hasRelatedWork W2980291101 @default.
• W2598392444 hasRelatedWork W2985655986 @default.
• W2598392444 isParatext "false" @default.
• W2598392444 isRetracted "false" @default.
• W2598392444 magId "2598392444" @default.
• W2598392444 workType "article" @default.